Introduction
============

Schizophrenia (SCZ) is a severely debilitating psychiatric disorder characterized by positive and negative symptoms as well as cognitive dysfunction ([@ref-1]; [@ref-16]). The lifetime risk of SCZ is approximately 1% across the world ([@ref-18]), and the lifetime prevalence of adults in China was 0.6% ([@ref-13]). SCZ has a marked impact on the life quality and accounts for approximately 2.8% of the global burden of diseases reported by the World Health Organization in 2001, and the prevalence of SCZ disability was 0.41% in China ([@ref-17]).

Genetic and environmental factors may combine to increase SCZ risk ([@ref-19]). Genetic factors explain \~80% of the risk for SCZ, and the risk of the SCZ decrease as the parental relationship recedes ([@ref-30]). Despite vigorous genome-wide association studies have been conducted to elucidate the common genetic variations associated with the susceptibility to SCZ ([@ref-5]; [@ref-21]), the etiology of SCZ remains obscure, suggesting that additional studies are required to discover the "missing heritability."

The voltage-gated calcium channel auxiliary subunit alpha2delta 2 gene (*CACNA2D2*), located in 3p21.31 and highly expressed in the brain, encodes a calcium channel protein. Voltage-gated calcium channels are widely distributed throughout the brain and mediate the intracellular Ca2+ influx of synaptic action potentials ([@ref-10]). In recent years, the gene encoding voltage-gated calcium channel subunit attracts wide attention in the field of SCZ pathogenesis. SNPs in calcium channel genes have been identified as genetic risk factors for a spectrum of psychiatric disorders ([@ref-7]; [@ref-6]). For example, several studies showed that SNPs of *CACNA1C* were significantly associated with SCZ, and the finding has been confirmed in different populations ([@ref-8]; [@ref-28]; [@ref-31]). Although there are no reported studies on the relationship between *CACNA2D2* and SCZ, *CACNA2D2* may cause other psychiatric disorders ([@ref-4]) and severe neurological diseases ([@ref-23]). In this study, we conducted a genetic association study to examine the association between SNPs of *CACNA2D2* and SCZ by a case-control study.

Materials and Methods
=====================

Study population
----------------

A total of 761 patients with SCZ from the Mental Hospital of Changchun and 775 healthy controls from the physical examination center of the First Hospital of Jilin University were recruited. All participants were Han Chinese. The patients were diagnosed according to the criteria of the International Statistical Classification of Disease and Related Health Problems, Tenth Revision (ICD-10) independently by at least two experienced psychiatrists. Healthy controls matched the patients by gender and age. All controls had no personal or family history of mental illness. This study was performed under protocols approved by the Ethics Committee of Jilin University, China (2014-05-01). All subjects signed written informed consent before participating in this study, and all experiments were performed in accordance with relevant guidelines and regulations.

DNA extraction and SNP selection
--------------------------------

Peripheral blood of five mL was collected from each subject, and the genomic DNA was extracted from blood samples using a commercial DNA extraction kit (Kangwei Biotech Company, Beijing, China). SNPs located in the promoter and 3′ untranslated region (UTR) of *CACNA2D2* were searched in NCBI-SNP (<https://www.ncbi.nlm.nih.gov/snp/>) and Ensembl (<https://asia.ensembl.org/>) databases. We predicted the function of these SNPs in SNPinfo (<https://snpinfo.niehs.nih.gov/>) and searched for minor allele frequency (MAF) each SNP in 1,000 Genomes. Finally, we chose three SNPs (MAF \> 0.05) located in promoter or 3′UTR regions (rs3806706 in the promoter region and rs45536634 and rs12496815 in the 3′ UTR) of *CACNA2D2* and predicted to be located in transcription factor binding sites. SNP genotyping was performed using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). SNP genotyping reactions were performed in a 384-well Spectro-CHIP using a Mass Array nanodispenser (Sequenom Inc., San Diego, CA, USA). The primers for genotyping were designed by AssayDesigner3.1 and were listed in [Table 1](#table-1){ref-type="table"}.
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###### Primers for polymerase chain reaction.
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  SNP          Primer sequence (5′--3′)
  ------------ -----------------------------------
  rs12496815   F: ACGTTGGATGTGGTTTTGGCACCAGTGCGT
               R: ACGTTGGATGTGGCACCCAAATCACATCTC
  rs3806706    F: ACGTTGGATGTGAGCTCAACAGCTGCCTTC
               R: ACGTTGGATGGTCCAGCAAACAGGTAAGAG
  rs45536634   F: ACGTTGGATGCAATGTATGTCAAGGGCCTG
               R: ACGTTGGATGGAGTCCCACTTAGTGCTCTG

Statistical analysis
--------------------

Pearson's Chi-square (χ^*2*^) test and Student's *t*-test were used to test the distribution of sex and age between case and control groups, respectively. The distributions of allele and genotype were analyzed using χ^*2*^ tests. The odds ratio (OR) was used to estimate the relative risk of SCZ associated with genotypes with minor alleles. The Type I error due to multiple testing was corrected by the FDR method. All the above analyses were performed using Software SPSS 24.0 (IBM SPSS, IBM Corp, Armonk, NY, USA), and R version 3.2.3 was used for FDR corrections. The Hardy--Weinberg equilibrium (HWE) test was conducted in the case and control group separately by Goodness of fit χ^2^ test using online software SNPStats (<https://www.snpstats.net/snpstats/start.htm>). The linkage disequilibrium (LD) between SNPs was estimated in both females and males separately using Haploview 4.2 ([@ref-2]), and the haplotype analysis was further performed using Haploview. The statistical power for each SNP was calculated according to the MAF of each SNP (rs45536634: 0.073, rs3806706: 0.378 and rs12496815: 0.388). The prevalence of SCZ (1%) was estimated by Quanto 1.2.4 ([@ref-9]). The OR was set from 1.4 to 2.0. All tests were two-sided and *P*~adj~-value less than 0.05 was considered to be statistically significant.

Results
=======

Demographic characteristics
---------------------------

A total of 1,536 subjects were included in this study, comprised of 761 SCZ patients (58.2% males, Mean age = 34.61 ± 12.02 years) and 775 healthy controls (56.2% males, Mean age = 34.74 ± 11.41 years). There was no significant difference either in sex (χ^*2*^ = 0.681, *P* = 0.409) or age (*t* = 0.221, *P* = 0.825) between patients and healthy controls. The results of the HWE test were shown in [Table 2](#table-2){ref-type="table"}. All SNPs were in accordance with the HWE in both cases and controls (*P* \> 0.05).
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###### Test of HWE for case and control groups.
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  Gene         SNP          Case    Control                                         
  ------------ ------------ ------- --------- ------- ----- ------- ------- ------- -------
  *CACNA2D2*   rs45536634   0.172   0.171     0.024   0.9   0.127   0.137   2.42    0.12
               rs12496815   0.469   0.497     2.126   0.1   0.498   0.499   0.002   0.968
               rs3806706    0.458   0.437     1.66    0.2   0.403   0.422   1.583   0.208

**Note:**

Ho, observed heterozygosity; He, expected heterozygosity.

The distribution of alleles and genotypes in males and females
--------------------------------------------------------------

The detection rate of rs45536634, rs12496815 and rs3806706 were 97%, 92% and 98%, respectively. Genotype and allele frequencies of females were depicted in [Table 3](#table-3){ref-type="table"}. A significant difference (*P*~ajd~ = 0.012) was observed in allele frequencies of rs45536634 between female SCZ patients and female healthy controls. Subjects who carried minor allele A had a 1.9 times higher risk of SCZ than those homozygous for the major G allele. Similarly, a significant difference (*P*~ajd~ = 0.006) was observed in the genotype distribution in females, and subjects with the minor allele (GA + AA) has an increased risk of SCZ when compared those with genotype GG (OR = 1.931, 95% CI \[1.259--2.963\]). These associations were found only in females, but not in males. In the male group, there was a difference between cases and controls in the genotype distribution of rs3806706 (*P* = 0.02); however, after adjusting for multiple testing, the difference was not significant (*P*~ajd~ = 0.12) ([Table 4](#table-4){ref-type="table"}).
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###### Genotype and allele distributions of *CACNA2D2* SNPs in female.
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  SNPs         Genotype   Case   Control   χ^*2*^   *P*     *P*~adj~                                OR \[95% CI\]
  ------------ ---------- ------ --------- -------- ------- --------------------------------------- --------------------------------------------------------
  rs3806706    GG         140    158       0.032    0.858   0.858                                   1
               GC + CC    165    181                                                                1.184 \[0.689--2.035\]
               Allele                                                                               
               G          417    460       0.039    0.843   0.858                                   1
               C          193    218                                                                0.977 \[0.772--1.235\]
  rs45536634   GG         227    297       9.275    0.002   0.006[\*](#table-3fn2){ref-type="fn"}   1
               GA + AA    62     42                                                                 1.931 \[1.259--2.963\][\*](#table-3fn2){ref-type="fn"}
               Allele                      9.545    0.002   0.006[\*](#table-3fn2){ref-type="fn"}   
               G          513    635                                                                1
               A          65     43                                                                 1.871 \[1.251--2.798\][\*](#table-3fn2){ref-type="fn"}
  rs12496815   GG         62     69        1.421    0.233   0.395                                   1
               GA + AA    190    268                                                                0.789 \[0.534--1.165\]
               Allele                                                                               
               G          247    308       1.268    0.263   0.395                                   1
               A          257    366                                                                0.876 \[0.695--1.103\]

**Notes:**

*P*~adj~ represent *P* corrected by FDR.

*P*~adj~ \< 0.05.
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###### Genotype and allele distributions of *CACNA2D2* SNPs in male.
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  SNPs         Genotype   Case   Control   χ^*2*^    *P*     *P*~adj~   OR \[95% CI\]
  ------------ ---------- ------ --------- --------- ------- ---------- ------------------------
  rs3806706    GG         190    225       5.373     0.02    0.12       1
               GC + CC    241    208                                    1.372 \[1.050--1.793\]
               Allele                                                   
               G          580    617       3.185     0.074   0.172      1
               C          282    249                                    1.205 \[0.982--1.478\]
  rs45536634   GG         361    369       0.127     0.721   0.865      1
               GA + AA    67     64                                     1.070 \[0.738--1.552\]
               Allele                      0.00025   0.987   0.987      
               G          786    795                                    1
               A          70     71                                     1.997 \[0.707--1.407\]
  rs12496815   GG         85     105       0.66      0.416   0.624      1
               GA + AA    303    327                                    1.145 \[0.826--1.586\]
               Allele                                                   
               G          347    423       2.953     0.086   0.172      1
               A          429    441                                    1.186 \[0.976--1.440\]

**Note:**

*P*~adj~ represent *P* corrected by FDR.

LD and haplotype analysis
-------------------------

As shown in [Fig. 1](#fig-1){ref-type="fig"}, the LD analysis of rs45536634 and rs12496815 in *CACNA2D2* showed that the D' values were equal to one in both female and male groups. According to the results of LD analysis, haplotype association analyses of rs45536634--rs12496815 were conducted in females and males respectively, and the results are shown in [Table 5](#table-5){ref-type="table"}. Three common haplotypes were estimated to have a frequency \> 1%, and haplotype AG was significantly associated with SCZ (OR = 1.91, *P*~adj~ = 0.0096) in females.

![Linkage disequilibrium (LD) of SNPs within *CACNA2D2* in female (A) and male (B) D' values were used toestimate the LD between pairwise SNPs.](peerj-08-8521-g001){#fig-1}
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###### Association between haplotypes and schizophrenia by sex.
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  Haplotype                            Male (frequency)   Female (frequency)                                                                                           
  ------------------------------------ ------------------ -------------------- --------------------- ------- ------- -------- -------- ---------------------- -------- ---------------------------------------
  rs45536634--rs12496815                                                                                                                                               
  GA                                   0.5105             0.5518               1                     --      --      0.5424   0.5069   1                      --       --
  GG                                   0.4075             0.3666               0.84 \[0.68--1.03\]   0.086   0.28    0.3942   0.3807   1.02 \[0.80--1.31\]    0.87     0.87
  AG                                   0.082              0.0816               0.93 \[0.66--1.31\]   0.66    0.7     0.0634   0.1125   1.91 \[1.26--2.90\]    0.0026   0.026[\*](#table-5fn1){ref-type="fn"}
  AA                                   0                  0                                          --      --      0        0                               --       --
  rs124996815--rs3806706                                                                                                                                               
  GG                                   0.4462             0.3933               1                                     0.4098   0.4196   1                      --       --
  AG                                   0.2659             0.2796               1.18 \[0.92--1.51\]   0.18    0.3     0.2686   0.264    0.96 \[0.71--1.29\]    0.77     0.87
  AC                                   0.2439             0.2752               1.27 \[1.00--1.61\]   0.046   0.23    0.2742   0.2473   0.88 \[0.66--1.16\]    0.37     0.74
  GC                                   0.044              0.0519               1.33 \[0.77--2.29\]   0.31    0.388   0.0473   0.0691   1.43 \[0.77--2.62\]    0.26     0.65
  rs124996815--rs3806706--rs45536634                                                                                                                                   
  GGG                                  0.3712             0.3148               1                     --      --      0.3492   0.3297   1                      --       --
  AGG                                  0.266              0.2798               1.23 \[0.95--1.59\]   0.12    0.28    0.2683   0.2598   1.04 \[0.76--1.43\]    0.79     0.87
  ACG                                  0.2439             0.2735               1.31 \[1.03--1.69\]   0.031   0.23    0.2741   0.2496   0.97 \[0.72--1.31\]    0.85     0.87
  GGA                                  0.0749             0.0782               1.23 \[0.83--1.81\]   0.3     0.288   0.061    0.0941   1.67 \[1.02--2.72\]    0.042    0.167
  GCG                                  0.0369             0.0502               1.58 \[0.87--2.87\]   0.14    0.28    0.045    0.0482   1.18 \[0.60--2.34\]    0.63     0.87
  rare                                 0.0071             0.0035               0.72 \[0.13--3.85\]   0.7     0.7     0.0024   0.0186   8.05 \[1.01--64.35\]   0.05     0.167

**Note:**

*P*~adj~ \< 0.05.

Statistical power
-----------------

The statistical power for rs45536634, rs12496815 and rs3806706 were 0.675--0.999, 0.872--0.999 and 0.878--0.999, respectively, if the OR varied from 1.4 to 2.0.

Discussion
==========

The association between variants of a number of genes and SCZ has been reported in previous studies. To the best of our knowledge, this is the first report of a significant association between rs45536634 of *CACNA2D2* and SCZ in females of the Northeast Han Chinese population.

It is known that Ca2+ ion represents one of the most important second messengers in the brain and plays an essential role in neuronal development, synaptic transmission and plasticity, besides regulating various metabolic pathways ([@ref-22]). Notably, as demonstrated by several studies, the Ca2+ homeostasis disorder is associated with many pathological mechanisms, especially those related to neurodegenerative disorders, such as SCZ, Alzheimer's disease, and bipolar disorder ([@ref-4]; [@ref-24]). *CACNA2D2* encodes the Alpha 2 delta 2 subunit of voltage-gated calcium channel ([@ref-25]) which is a key signaling element, allowing changes in membrane potential to control a large number of Ca2+ dependent neurotransmitter release and neuronal plasticity in electrically excitable cells ([@ref-22]). A study conducted by [@ref-26] showed that the copy number change in *CACNA2D2* was a risk factor for Alzheimer's disease.

Moreover, *CACNA1C*, a gene in the same family as *CACNA2D2*, has been repeatedly confirmed as one of the susceptibility genes for SCZ in various populations ([@ref-11]; [@ref-12]). In addition, [@ref-29] conducted a review research on calcium channel genes associated with SCZ in the Han Chinese population and found that *CACNA1C*, *CACNB2*, *CACNA2D1* and *CACNA2D3* were related to SCZ.

The sex-specific molecular phenotype of SCZ was observed in previous studies. A study conducted by Oumaima et al. indicated that minor alleles of SNPs in genes *LTA* and *TNFA* were over-represented in male SCZ patients but not in female schizophrenia patients ([@ref-14]). [@ref-15] researched the association between the functional polymorphism of *IFNGR2* with SCZ and found the *IFNGR2 Q64R* polymorphism was associated with SCZ in males. The study conducted by [@ref-27] showed that the genotypes and allele distributions of rs3087494 in *PLA2G12A* were significantly associated with SCZ in males, but not in females. Another study focused on sex-specific molecular phenotypes found that eight genes showed a differential expression in female and male schizophrenia patients ([@ref-20]).

For a better understanding of the association between SCZ and *CACNA2D2*, a more in-depth investigation---haplotype analysis was carried out to determine whether the combination of specific alleles was associated with the SCZ risk. The AG haplotype, consisted of rs44536634 and rs12496815 alleles, was correlated with an increased risk of SCZ in Han Chinese women. The haplotype analysis not only confirmed the association between rs44536634 and SCZ, but also supported that rs44536634 allele A was associated with an increased risk of SCZ in females. Furthermore, our research provided an evidence to support the distinct molecular phenotypes of SCZ patients with different gender, as reported in previous studies ([@ref-3]; [@ref-15]; [@ref-20]).

In this study, several limitations should be considered. Firstly, our study was performed at a single center and only three SNPs were analyzed, it ignored SNPs in other genes that may be associated with SCZ. Secondly, the study is limited to interpreting the causal relationship between genetic risk factors and SCZ as this is a cross-sectional study. Furthermore, the representative of this study was limited to the adults of Northeast China because the samples were collected from Jilin Province. Finally, we lost some demographic covariates of the controls when analyzing the association between *CACNA2D2* SNP polymorphism and SCZ patients due to the difficulty of demographic characteristics collection. Large-scale examination with more demographic characteristics is warranted to further examine the association between *CACNA2D2* and SCZ.

Conclusion
==========

The sample size of the present study was sufficient for detecting the effect of *CACNA2D2* variants on SCZ. This study demonstrated that *CACNA2D2* polymorphisms might influence the susceptibility to SCZ in Han Chinese women from Northeast China. The findings support the hypothesis that *CACNA2D2* may represent a novel susceptibility gene for SCZ in females. Functional genomics studies should be performed in future to validate the function of SCZ-associated *CACNA2D2* variants.
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